fda approval of adjuvant dabrafenib/trametinib in braf melanoma
Published 6 years ago • 485 plays • Length 1:08Download video MP4
Download video MP3
Similar videos
-
0:30
dr. postow on fda approval of adjuvant dabrafenib plus trametinib in braf-mutant melanoma
-
1:11
dr. weber on the fda approval of adjuvant dabrafenib/trametinib in braf-mutant melanoma
-
0:18
copy of dr. weber on the fda approval of adjuvant dabrafenib/trametinib in braf-mutant melanoma
-
1:31
dr. daud on dabrafenib/trametinib vs immunotherapy in melanoma
-
1:24
dr. algazi on benefit of continuous dabrafenib/trametinib dosing in braf melanoma
-
1:46
dr. weber on dabrafenib/trametinib approval for melanoma
-
4:12
adjuvant therapy in melanoma: combi-ad trial
-
0:59
the success of the dabrafenib and trametinib combination in braf-mutated melanoma
-
1:52
dr. long on dabrafenib/trametinib in braf v600e-mutant melanoma
-
4:08
updates from combi-ad: dabrafenib and trametinib for melanoma
-
2:16
dr. rodabe n. amaria on dabrafenib plus trametinib in melanoma
-
1:26
dr. nathan on long-term outcomes with dabrafenib/trametinib in braf v600-mutant melanoma
-
5:54
two fda approvals, braf/mek breakthrough status in nsclc, and more
-
2:19
dr. robert on 5-year analysis of dabrafenib/trametinib in braf v600-mutant melanoma
-
0:44
dr. michael rotkowitz on dabrafenib and trametinib combination side effects
-
1:24
adverse events with dabrafenib/trametinib combination in melanoma
-
1:24
adverse events with dabrafenib/trametinib combination in melanoma
-
1:04
dr. wilson on long-term data with dabrafenib plus trametinib in melanoma
-
3:06
combi-d: phase 3 trial of dabrafenib plus trametinib in braf v600e/k-mutated melanoma